Ipsen · Company

Onivyde/NALIRIFOX (NAPOLI 3), Cabometyx (ex-US), tazemetostat (Tazverik), Ojemda (tovorafenib, EU rights from Day One).

Headquarters

Paris, FR

Type

pharma · IPN.PA

Website

www.ipsen.com

Products

6top

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

NALIRIFOX is a version of FOLFIRINOX using a liposome-wrapped irinotecan, approved in 2024 as a first-line option for metastatic pancreatic cancer.

ApprovedSmall-molecule type II RAF inhibitor

Tovorafenib · Ojemda

Tovorafenib is a pill for the most common childhood brain tumour, low-grade glioma driven by BRAF changes, approved in 2024.

ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)

Cabozantinib · Cabometyx

A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

Not mapped hereTopoisomerase I inhibitor (camptothecin prodrug)

Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde

Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.

ApprovedPeptide hormone analogue (SSTR2 agonist)

Somatostatin analogues (octreotide, lanreotide) · Sandostatin LAR, Somatuline Depot

Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.

WithdrawnSmall-molecule EZH2 inhibitor

Tazemetostat · Tazverik

Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.